Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesKiora Pharmaceuticals Inc

Kiora Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.34 USD -0.01 ( 0.74%)
Last update at 2026-11-12T15:11:00Z
VOLUME
3701
Market Cap
11.50M

Momentum Score

…

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.33
Low
1.34
High
52 Week Price Range
1.76
Low
2.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for ocular surface diseases, including severe dry eye and corneal disorders. Long-term growth may be driven by successful clinical progress, regulatory approvals, and potential collaborations to support commercialization, and investors may find the company attractive for its focused pipeline addressing unmet needs in ophthalmology with upside tied to milestone execution.

Material risks include reliance on positive clinical trial results, regulatory uncertainty, a limited cash runway likely requiring additional financing, and competition from larger ophthalmology and biotechnology firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.35
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-3.88M
Debt / Equity
0.02
ROE
-56.37%
Net Debt
-8.33M
ROCE
-58.66%
Diluted EPS TTM
-2.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.12M 5.66M -12.42M -13.70M -16.70M
Net income -10.84M 3.59M -12.51M -13.58M -16.39M
Selling general administrative 5.75M 5.54M 4.66M 8.28M 5.32M
Selling and marketing expenses - - 0.06M - -
Gross profit -0.02M 16.00M -4.03M - -
Reconciled depreciation 0.02M 0.02M 0.05M 0.04M 0.05M
Ebit -12.10M 5.68M -12.41M -12.31M -16.94M
Ebitda -12.07M 5.70M -12.36M -11.63M -10.63M
Depreciation and amortization 0.02M 0.02M 0.05M 0.68M 6.31M
Operating income -9.46M 4.51M -12.59M -12.31M -16.94M
Other operating expenses 9.46M 11.49M 12.59M 11.73M 10.67M
Interest expense 0.02M 0.02M 0.01M 0.01M 0.01M
Tax provision -1.28M 2.07M 0.09M -0.11M -0.30M
Interest income 0.89M 1.25M 0.18M 0.06M 0.00M
Net interest income 0.87M 1.23M 0.17M 0.05M -0.01M
Income tax expense -1.28M 2.07M 0.09M -0.11M -0.30M
Total revenue 0.00M 16.00M 0.00M 0.00M 0.00M
Total operating expenses 9.43M 11.49M 12.59M 11.73M 10.67M
Cost of revenue 0.02M 0.38M 4.03M - -
Total other income expense net -2.66M 1.15M 0.16M -1.39M 0.24M
Net income from continuing ops -10.84M 3.59M -12.74M -13.58M -16.39M
Net income applicable to common shares - - - - -16.39M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 24.25M 36.48M 13.71M 18.68M 18.06M
Intangible assets 2.06M 6.69M 8.81M 10.74M 8.70M
Other current assets 1.34M 2.31M 0.23M 0.34M 0.61M
Total liab 8.13M 10.72M 7.60M 7.27M 8.83M
Total stockholder equity 16.13M 25.76M 6.11M 11.41M 9.22M
Deferred long term liab - - - - 8.53M
Other current liab 1.16M 5.57M 1.38M 2.16M 1.33M
Common stock 0.28M 0.27M 0.08M 0.02M 0.13M
Capital stock 0.28M 0.27M 0.08M 0.02M 0.13M
Retained earnings -154.22M -143.38M -146.98M -134.46M -124.73M
Other liab - - - - 7.13M
Good will - - - - 0.00M
Other assets - - 0.00M - 8.62M
Cash 8.70M 3.79M 2.45M 5.96M 7.85M
Total current liabilities 3.63M 6.01M 1.63M 3.27M 1.61M
Current deferred revenue 1.25M - - - -
Net debt -8.33M -3.74M -2.35M -5.86M -7.65M
Short term debt 0.16M 0.02M 0.05M 0.11M 0.12M
Short long term debt total 0.37M 0.06M 0.11M 0.11M 0.21M
Other stockholder equity 170.31M 169.16M 153.19M 146.04M 133.92M
Property plant equipment - - - - 0.28M
Total current assets 21.75M 29.71M 4.74M 7.68M 8.99M
Net tangible assets - - - - 9.06M
Short term investments 8.39M 23.00M - - -
Net receivables 3.32M 0.60M 2.05M 1.37M 0.53M
Inventory - - 0.00M - -
Accounts payable 1.06M 0.42M 0.21M 1.01M 0.16M
Accumulated other comprehensive income -0.25M -0.28M -0.18M -0.18M -0.09M
Non currrent assets other 0.06M 0.02M 0.04M 0.08M 0.09M
Non current assets total 2.50M 6.78M 8.97M 11.00M 9.07M
Capital lease obligations 0.37M 0.06M 0.11M 0.11M 0.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 14.54M -22.66M 0.00M 0.01M -0.16M
Change to liabilities - - - - -0.75M
Total cashflows from investing activities 14.43M -22.66M - - -0.16M
Net borrowings 0.00M 0.00M - - -0.21M
Total cash from financing activities 0.27M 15.50M 5.97M 8.62M 17.80M
Change to operating activities - - - - -0.28M
Net income -10.84M 3.59M -12.51M -13.58M -16.39M
Change in cash 4.90M 1.34M -3.55M -1.89M 6.67M
Begin period cash flow 3.80M 2.46M 6.01M 7.90M 1.23M
End period cash flow 8.70M 3.80M 2.46M 6.01M 7.90M
Total cash from operating activities -9.96M 8.56M -9.56M -10.43M -10.89M
Issuance of capital stock 0.00M 15.00M 6.46M 5.38M 18.75M
Depreciation 0.02M 0.02M 0.05M 0.04M 0.05M
Change to account receivables -2.41M 1.03M -0.55M - -
Sale purchase of stock - - 0.00M -0.02M -
Other cashflows from financing activities 0.27M 0.50M -1.00M 3.26M -0.95M
Change to netincome - - - - 6.32M
Capital expenditures 0.11M 0.01M 0.00M 0.00M 0.06M
Change in working capital -3.27M 3.67M -1.82M 0.67M -1.04M
Stock based compensation 0.90M 0.66M 0.75M 0.46M 0.84M
Other non cash items 3.61M 0.91M 3.88M 2.10M 5.96M
Free cash flow -10.07M 8.55M -9.56M -10.43M -10.95M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KPRX
Kiora Pharmaceuticals Inc		 -0.01
0.74%		 1.34 - 2.41 0.14 0.70 13.31 -1.03
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

332 Encinitas Boulevard, Encinitas, CA, United States, 92024

858 224 9600

https://www.kiorapharma.com

13

Name Title Year Born
Dr. Brian M. Strem Ph.D. Pres, CEO, Principal Financial & Accounting Officer and Director 1979
Dr. Eric J. Daniels M.B.A., M.D. Chief Devel. Officer 1973
Dr. Stefan Sperl Ph.D. Exec. VP of CMC & Operations NA
Ms. Melissa Tosca Exec. VP of Fin. NA
Dr. MaryJane Rafii Ph.D. Consultant NA
Dr. Brian M. Strem Ph.D. President, CEO & Director 1980
Ms. Melissa Tosca CPA Executive Vice President of Finance 1981
Dr. Eric J. Daniels M.B.A., M.D. Chief Development Officer 1974
Dr. Stefan Sperl Ph.D. Executive Vice President of CMC & Operations NA
Ms. Melissa Tosca CPA Chief Financial Officer 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…